1. Home
  2. Labeler Index
  3. Remedyrepack Inc.
  4. 70518-3951
  5. Product Images: Clopidogrel

Product Images Clopidogrel

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Clopidogrel NDC 70518-3951 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

This is a description for a medication called "Clopidogrel" in tablet form. The tablet contains 75 mg of the active ingredient. The quantity of tablets in the package is 30. The text also provides information about the prescription status of the medication, the NDC code, the expiration date, and the lot number. The source NDC is listed as 69367-0200-05. The manufacturer is Westminster Pharmaceutics, LLC, located in Clive Branch, MS 38654. The text also emphasizes the importance of keeping the medication out of the reach of children. The directions for use can be found in the package insert. The recommended storage conditions are between 20-25°C (58-77°F), with excursions permitted up to 15.30°C (59-86°F) according to USP guidelines. Lastly, the text mentions that the medication has been repackaged by RemedyRepack, Inc. located in Indiana, PA 15701.*

Figure 1 - clopidogrel 01

Figure 1 - clopidogrel 01

Figure 1 - clopidogrel 02

Figure 1 - clopidogrel 02

Figure 2 - clopidogrel 03

Figure 2 - clopidogrel 03

Figure 3 - clopidogrel 04

Figure 3 - clopidogrel 04

Figure 3 - clopidogrel 05

Figure 3 - clopidogrel 05

Figure 4 - clopidogrel 06

Figure 4 - clopidogrel 06

The given text appears to be a statistical analysis of deaths related to a treatment (possibly a drug called Clopidogrel) compared to a placebo. It includes the number of deaths in each group (1845 deaths in the placebo group and 1726 deaths in the Clopidogrel group) and indicates a 7% reduction in risk of death with Clopidogrel, with a p-value of 0.03. The last line mentions "Days since randomi", which may refer to the duration of the study or the time since randomization.*

Figure 5 - clopidogrel 07

Figure 5 - clopidogrel 07

This text appears to be a statistical analysis of the effectiveness of a medication called Clopidogrel compared to a placebo. The study evaluated the occurrence of death, re-infarction (another heart attack), or stroke before the first discharge. The results show that out of 2310 participants in the placebo group, 10.1% experienced the events, while out of 2121 participants in the Clopidogrel group, 9.2% experienced the events. This indicates a 9% reduction in risk with Clopidogrel compared to the placebo, and the result is statistically significant (p=0.002). The data is presented over a 28-day period, with the number of days since randomization mentioned.*

Figure 6 - clopidogrel 08

Figure 6 - clopidogrel 08

Figure 7 - clopidogrel 09

Figure 7 - clopidogrel 09

Figure 8 - clopidogrel 10

Figure 8 - clopidogrel 10

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.